Home » Health Care & Life Sciences

Health Care & Life Sciences

Articles

BATTEN: FTC could resolve antitrust concerns on health care reform

President Obama recently announced a cooperative initiative where health care industry leaders plan to
work together to reform the ailing health care system. Shortly after that announcement, the national
media machine spawned considerable concern among several health care groups that the cooperative effort might violate
federal antitrust laws for collusion and price fixing among competitors.

Read More

State law aims to attract doctors to areas in need of care

A state law that went into effect July 1 attempts to attract young physicians and mental health practitioners to underserved
areas by forgiving part of their student loans. But Indiana’s budget woes prevented lawmakers from allocating funds
to support the program.

Read More

Conseco reinsurance deal swaps profits for cash

Carmel-based Conseco Inc., still a bit strapped for cash, brought in a reinsurance company to shoulder some of the risk
of its life insurance policies. Minnesota-based Wilton Reassurance Co. will pay $57.5 million to Conseco as a ceding
commission to co-insure and administer 104,000 policies held by Conseco subsidiaries.

Read More

Hilbert in-law’s life insurance dispute takes odd turn

Local businessman J.B. Carlson contends the $15 million life insurance policy he took out on Stephen Hilbert’s mother-in-law
was legitimate, because she served on his firm’s board and was a key decision-maker. The mother-in-law, Germaine
“Suzy” Tomlinson, died at age 74 last September—just 32 months after the policy was issued.

Read More

Lilly asks FDA to review weekly diabetes drug

Drugmakers Eli Lilly and Co., Amylin Pharmaceuticals Inc. and Alkermes Inc. said yesterday that the U.S. Food and Drug Administration
has accepted their application for the once-a-week diabetes drug exenatide.

Read More

Indianapolis benefits firms merge

Two Indianapolis benefits consulting firms have finalized their merger, the companies announced this morning. Terms of the
deal between Benefit Associates Inc. and Benefit Consultants Inc., in the works since March, were not disclosed.

Read More

Lilly cancer drug OK’d for new use

Eli Lilly and Co.’s top rising-star drug has been approved by U.S. regulators for a new use, an event that could boost sales of
the medication. Alimta, a lung cancer drug, was approved as a maintenance therapy for non-small cell lung cancer
for certain patients, Lilly announced today.

Read More

Lilly kicks lobbying into high gear

Once again, Indianapolis-based Eli Lilly and Co. is running in the lead pack in dollars spent to bend ears on Capitol Hill. And that was even before the health care reform debate got rolling.

Read More

Minority suppliers diversifying into life sciences

The Indiana Minority Supplier Development Council has made life sciences companies its latest target—part of an even larger effort to attract minorities to the burgeoning life sciences industry under
way on a national scale.

Read More

If Dow AgroSciences sells, let’s hope it’s not to a rival

Private equity firms have a reputation as ruthless acquirers. They slash fat and jettison sluggish product lines, all in a quest to wring out higher profits and grow the parts of the business with the most potential. For Indianapolis-based Dow AgroSciences—or at least for its 1,200 local employees—a buyer like that would be a godsend. […]

Read More